Freeline Therapeutics Holdings plc Overview

Freeline Therapeutics Holdings plc Research & Development

Research & Development expenses for FRLN.

Quarterly R&D Expenses

$5.79M

↓ 60.83% YoY

As of Sep 30, 2023

Annual R&D Expenses (TTM)

$38.15M

↓ 51.19% YoY

Trailing 12 months ending Sep 30, 2023

Average R&D Expenses (Comparison Companies)

Research & Development History

Research & Development Comparison

Annual Research & Development Growth Rate (%)

Annual Research & Development Growth (Absolute)

Jump to metric

Total Revenue Cost of Revenue Gross Profit Research & Development Selling, General & Admin Operating Income Other Income Expense Net EBIT Income Tax Net Income Profit Margin